| Substance | Condition | Seq | Src | PMID | Dtl | Title |
| Hyperoside | Bone Disease | 1 | PM | 35435096 | 📋 | Hyperoside suppresses osteoclasts differentiation and function through downregulating TRAF6/p38 MAPK signaling pathway |
| Hyperoside | Degenerative Disk Disease | 1 | PM | 35730622 | 📋 | Hyperoside ameliorates TNF‑α‑induced inflammation, ECM degradation and ER stress‑mediated apoptosis via the SIRT1/NF‑κB and Nrf2/ARE signaling pathways in vitro |
| Hyperoside | Osteoarthritis | 1 | PM | 33130473 | 📋 | Hyperoside ameliorates the progression of osteoarthritis: An in vitro and in vivo study |
| Hyperoside | Osteonecrosis | 1 | PM | 35331079 | 📋 | Hyperoside exerts osteoprotective effect on dexamethasone-induced osteoblasts by targeting NADPH Oxidase 4 (NOX4) to inhibit the reactive oxygen species (ROS) accumulation and activate c-Jun N-terminal kinase (JNK) pathway |
| Hyperoside | Osteoporosis | 1 | PM | 38797313 | 📋 | Effect of hyperoside on osteoporosis in ovariectomized mice through estrogen receptor α/ITG β3 signaling pathway |
| Hyperoside | Postmenopausal Osteoporosis | 1 | PM | 37157916 | 📋 | Hyperoside alleviates postmenopausal osteoporosis via regulating miR-19a-5p/IL-17A axis |
